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INTRODUCTION
The incidence of diabetes insipidus (DI) in pregnancy is rare, affecting 2 to 4 cases per 
100,000 gestations. Management of pre-gestational DI poses a challenge for patients 
who are already on 1-deamino-8-D-arginine vasopressin (desmopressin acetate, 
DDAVP) as limited data is available on DDAVP adjustments during pregnancy. This 
case series describes the changes in DDAVP daily requirements in three patients  
with pre-gestational central diabetes insipidus.
CASE PRESENTATION
Case 1: A 28 year old female with central DI from Langerhans cell histiocytosis was 
on DDAVP nasal spray 10 mcg twice daily pre-pregnancy. At 16 weeks gestation,  
she reported symptoms of polyuria and polydipsia and DDAVP was increased to  
20 mcg twice daily. Urine osmolality trended down by 67% (146 mOsm/kg) at  
24 weeks gestation but serum sodium (136-143 mmol/L) remained in normal range. 
Case 2: A 30 year old female with central DI from a concussion was on DDAVP tablet 
50 mcg twice daily pre-pregnancy. Increased polydipsia was reported during the first 
trimester, however self-reported polyuria occurred at 23 weeks. At this time DDAVP 
was increased to 150 mcg. Urine osmolality trended down by 52% at 27 weeks 
gestation (237 mOsm/kg) while serum sodium (134-137mmol/L) remained stable.
Case 3: A 34 year old female with congenital central DI was on DDAVP tablet 300 mcg 
total daily dose, pre-pregnancy. During her first pregnancy DDAVP was increased to 
500 mcg at 10 weeks gestation due to polyuria and polydipsia. During her second 
pregnancy DDAVP was increased to 600 mcg at 18 weeks gestation. Serum sodium 
levels (135-138 mmol/L) in second pregnancy remained stable in normal range.  
Post-partum, all three patients resumed pre-pregnancy DDAVP dose.
Patient  
Case
DDAVP dose  
pre-pregnancy
DDAVP dose  
intra-partum 
% Increase  
in dose 
1 20mcg* 40mcg* 100% 
2 100mcg# 150mcg# 50%
3 (1st) 300mcg# 500mcg# 66.7%
3 (2nd) 300mcg# 600mcg# 100%
*Nasal Spray #Tablet
DISCUSSION
Although the development and management of gestational DI is reviewed in several 
papers, there is limited information on the management of pregestational central DI  
in pregnancy. Physiologic changes in water homeostasis predispose pregnant  
women to develop symptoms of polyuria and polydipsia. It may therefore be difficult  
to determine if worsening symptoms are related to inadequate DDAVP dosing. 
Patients with pregestational central DI can perceive worsening symptoms as early  
as the first trimester. DDAVP doses increased by 50-100% between the second and 
third trimester correlating with a decline in urine osmolality by 53-67%. Serum sodium 
levels remained in normal range. Our goal is to share our clinical experience with 
managing pregestational DI in pregnancy. It is important to be aware of the physiological 
changes and how they correlate with fluctuations in DDAVP requirements. Future studies 
with larger numbers of pregnant women with pre-gestational DI may better define 
DDAVP requirements and help clinicians with expectant management during pregnancy.
